Molina Healthcare (MOH) Q3 Results Confront A Thin Margin Rebuild

Molina Healthcare came into this Q3 2026 print with a quietly improving chart, up about 13% over the past month, and a reputation as a discounted managed care turnaround story. The stock barely flinched on the day, rising about 0.8% to US$216.64. The headline was not the top line. Investors were reacting to a thin 0.6% adjusted pretax margin on US$10.5b of premium revenue and a medical cost ratio of 92.9%, which kept the focus squarely on whether this margin rebuild is real or just delayed.

Like the Molina Healthcare turnaround angle but uneasy with a 92.9% medical cost ratio and a 0.6% margin on US$10.5b of premiums? Compare this setup with our screener of insurers that pair tighter cost control with sturdier balance sheets through the list of solid balance sheet and fundamentals stocks (26 results).

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs. Q3 2025): US$10,582m vs. US$10,971m (revenue slightly lower year on year)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$38m vs. US$79m (profit roughly halved year on year)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.74 vs. US$1.50 (earnings per share declined sharply)
• Medical Cost Ratio, or MCR, and Adjusted Pretax Margin (Q3 2026): MCR 92.9% and adjusted pretax margin 0.6% on about US$10.5b of premium revenue (very thin profitability in the quarter)

Prefer clean charts instead of another dense wall of earnings commentary and cost ratios? See Molina Healthcare's full financial picture, including an easy visual read on its profitability trend and margin rebuild efforts, in the company report for Molina Healthcare.

Molina Embedded Earnings Story Faces Margin Reality Check

For Molina Healthcare, the bullish story hangs on converting “embedded” earnings into reported profit rather than chasing premium growth. That hinges on execution.

"The main thing that has to go right is Molina Healthcare converting underfunded Medicaid rates, duals margin improvement, and Marketplace downsizing into the targeted uplift in Medicaid MCR and embedded earnings without fresh EPS drags."

Q3 shows early but modest progress. Medicaid MCR at 93% and a 1.6% full year legacy Medicaid pretax margin point to some rate catch up, while duals are profitable and the MAPD exit is on track. Marketplace remains an EPS drag, yet guidance for breakeven in 2027 and reaffirmed 2026 EPS of at least US$5.25 indicate management still expects those embedded levers to translate into higher earnings.

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there.

Molina Bear Case: Membership Strain Still Unresolved

The bearish worry centers on Molina Healthcare winning contracts on paper while membership churn and weak products quietly drain earnings power.

"The ongoing decline in consolidated membership by 565,000 lives across the first half of 2026 risks leaving some of that capacity underutilized and could mean revenue and earnings fall short of those embedded expectations."

Q3 results neither close nor explode that gap. Premium revenue of about US$10.5b and a 0.6% adjusted pretax margin show early Medicaid repair, yet consolidated MCR at 92.9% and Marketplace losses guided at US$0.75 per share keep the membership erosion risk live rather than resolved.

Hunt Quiet Dislocations In Plain Sight

Molina Healthcare recently highlighted how thin margins can keep investors doubting a rebuild story. The real opportunity is recognizing stocks that could be undervalued before expectations and prices move closer together.

• Company 1 - 38% below our estimate - uses local pay-in and pay-out infrastructure that large online platforms integrate for complex emerging markets.
• Company 2 - 23% below our estimate - adds AI-focused data center optics projects as customers shift more compute to high bandwidth photonics.
• Company 3 - 43% below our estimate - scales solar tracking and control systems that utilities adopt for large multi year solar buildouts.

Three companies from the same screener. Open all 31 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com